- Home
- JPM vs LLY Comparison
JPM vs LLY Comparison
Compare JPM & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JPM | LLY |
|---|---|---|
| Founded | 1799 | 1876 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 902.2B | 994.5B |
| IPO Year | 2025 | 2007 |
Fundamental Metrics
Financial Performance| Metric | JPM | LLY |
|---|---|---|
| Price | $334.68 | $1,272.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 31 |
| Target Price | $372.57 | ★ $1,328.05 |
| AVG Volume (30 Days) | ★ 6.8M | 1.8M |
| Earning Date | 10-13-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.97% | 0.54% |
| EPS Growth | 1.37 | ★ 95.99 |
| EPS | 13.63 | ★ 16.19 |
| Revenue | ★ $182,447,000,000.00 | $65,179,000,000.00 |
| Revenue This Year | $13.98 | $35.86 |
| Revenue Next Year | $4.02 | $15.53 |
| P/E Ratio | ★ $24.59 | $79.48 |
| Revenue Growth | 2.75 | ★ 44.70 |
| 52 Week Low | $279.10 | $806.02 |
| 52 Week High | $366.50 | $1,311.75 |
Technical Indicators
Market Signals| Indicator | JPM | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 65.94 |
| Support Level | $325.28 | $1,122.01 |
| Resistance Level | $343.45 | $1,292.65 |
| Average True Range (ATR) | 5.66 | 32.09 |
| MACD | 0.95 | 12.09 |
| Stochastic Oscillator | 49.72 | 78.37 |
Price Performance
Historical ComparisonAbout JPM JP Morgan Chase & Co.
JPMorgan Chase is a leading global financial-services firm with operations in 66 countries and nearly 323,000 employees as of September 2026. Under the JPMorgan brands, the bank holding company boasts a $5.1 trillion balance sheet and $2.78 trillion in deposits as of September 2026. The firm generates its revenue across three core operating segments: consumer and community banking, the commercial and investment bank, and asset and wealth management. It maintains the top global ranking in investment banking fees with an 8.4% market share, serves millions of consumers through its network of over 5,000 US branches, and manages nearly $7.9 trillion in client assets within its wealth and asset management franchise.
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.